Nikki,
You might want to direct your questions to Genzyme or Infigen or the
Netherland government or the Finnish government or the US government.
Pharming  went into receivership but another company bought them out. (I can
get you the name)    This article is dated in 1999 and Infigen had 40
transgenic cows.  Last time I looked they had over 100.   Pharming had herds
in Finland, the goal was 2000--that was several years ago.  Your questions
are funny but I am afraid I have lost my sense of humor ...Valerie W. MClain,
IBCLC
PS:  Note the Finnish grant on human lactoferrin--and also remember that they
are testing a new kind of formula to prevent diabetes in Finland (quite a few
test sites there)

 http://www.pharming.com/News/highl_07_08_09_99.html
Pharming was granted a third US-patent on the purification of human
Lactoferrin from milk as well as an US-patent on expression in milk of
certain fusion proteins. This raises the total number of patents granted to
Pharming to 26.

Pharming's strong patent position was emphasized by an agreement with Genzyme
Transgenics Corporation granting them a non-exclusive license for the
production of human Serum Albumin in milk of transgenic cattle. Pharming
received an up-front payment of EUR 0.7 million and will receive further
fees, milestone payments and royalties in the future.

Pharming's partner for the development of human Factor VIII and human
Fibrinogen, the American Red Cross, received an US-patent broadly covering
stable liquid formulations of plasma proteins. Pharming is exclusively
licensed to this patent as it relates to human Factor VIII and human Factor
IX. The patented invention specifically relates to providing a constant level
of these coagulation factors in the blood to facilitate phrophylatic
treatment of hemophilia.

Tecnology development
In collaboration with Infigen Inc. from DeForest (Wisconsin, USA) Pharming is
making significant progress in the generation of transgenic cattle via
nuclear transfer. Recently Infigen reported it has generated as many as 40
animals via their proprietary technology. The animals are in good health and
display normal growth rates. A significant number of these animals are
genetically modified to carry transgenes for the production of
biopharmaceuticals in milk. The number of transgenic calves is expected to
increase steadily. To accommodate these calves Pharming recently completed a
state of the art pharmaceutical cattle farm in Vienna (close to Madison),
Wisconsin, where calves for the production of therapeutic proteins will be
raised.

Corporate affairs
Pharming obtained EUR 6 million in support from the Netherlands and Finnish
governments. The Netherlands support is a continuation of an already existing
Technical Development Credit scheme for the further development of human
Lactoferrin as well as human Collagen type I. The Finnish grant will be used
to finance the development of human Lactoferrin for nutraceutical purposes.




             ***********************************************
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html